Rani Therapeutics Holdings (RANI) Accounts Payables (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Accounts Payables of $858000.0 for Q1 2026, down 43.55% year-over-year from $1.5 million in Q1 2025, and up 177.67% quarter-over-quarter from $309000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Accounts Payables (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Accounts Payables history runs 7 years deep, the most recent figure standing at $858000.0 for Q1 2026.
- In Q1 2026, Accounts Payables fell 43.55% year-over-year to $858000.0; the TTM figure through Mar 2026 stood at $858000.0 (down 43.55% YoY), while the FY2025 annual figure was $309000.0, down 77.26% from the prior year.
- Accounts Payables for Q1 2026 stood at $858000.0, up from $309000.0 in the prior quarter.
- The five-year high for Accounts Payables was $2.5 million in Q3 2025, with the low at $309000.0 in Q4 2025.
- The 5-year median for Accounts Payables is $1.4 million (2023), against an average of $1.3 million.
- Peak annual rise in Accounts Payables reached 255.34% in 2025, while the deepest fall reached 77.26% in 2025.
- Rani Therapeutics Holdings' Accounts Payables stood at $1.5 million in 2022, then tumbled by 55.62% to $648000.0 in 2023, then surged by 109.72% to $1.4 million in 2024, then tumbled by 77.26% to $309000.0 in 2025, then surged by 177.67% to $858000.0 in 2026.
- Business Quant data shows RANI's Accounts Payables at $858000.0 in Q1 2026, $309000.0 in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | 1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.05 Mn |
| Mar 31, 2026 | 858,000.00 |
| Dec 31, 2025 | 309,000.00 |
| Sep 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.52 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 506,000.00 |
| Mar 31, 2024 | 806,000.00 |
| Dec 31, 2023 | 648,000.00 |
| Sep 30, 2023 | 1.41 Mn |
| Jun 30, 2023 | 1.04 Mn |
| Mar 31, 2023 | 1.51 Mn |
| Dec 31, 2022 | 1.46 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 1.44 Mn |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | 1.08 Mn |
| Sep 30, 2021 | 1.31 Mn |